> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for B+L’s Miebo
- URL: https://www.fdaweb.com/regulatory-review-period-for-b-ls-miebo/
- Published: 2024-08-15T12:00:00.000Z
- Updated: 2026-09-14T14:38:29.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157579

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Bausch + Lomb’s Miebo (perfluorohexyloctane), indicated for treating the signs and symptoms of dry eye disease. The regulatory review period is 2,018 days, of which 1,693 days occurred during the testing phase and 325 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-08-15/pdf/2024-18265.pdf?ref=fdaweb.com).